![ECOG-ACRIN logo[19516]275×75](https://blog-ecog-acrin.org/wp-content/uploads/2021/03/ECOG-ACRIN-logo19516275x75.png)
September 17, 2024
Summaries and links to timely information about research results in medical journals, recognition of research leaders, and more
August 14, 2024
Thoughts on the evolving clinical cancer research environment—and practice-changing results in acute lymphoblastic leukemia
August 22, 2024
This phase 3 study is comparing BRAF-targeted therapy with dabrafenib-trametinib to TKI therapy with cabozantinib in patients with disease progression following standard treatments
August 14, 2024
A Scientific Member of ECOG-ACRIN since 2012
August 14, 2024
Summaries of recently published ECOG-ACRIN research results
August 14, 2024
Summaries and links to timely information about research results in medical journals, recognition of research leaders, and more
July 3, 2024
GI Cancer Committee displays strong representation at ASCO; real-world data study nears activation; ECOG-ACRIN commends NCI's appointment of senior advisor for clinical research
July 3, 2024
The changes broaden eligibility for patients and permit more therapeutic options once enrolled in this randomized phase 3 trial, which explores the addition of radiotherapy to the usual treatment (chemotherapy) in people with esophagus and stomach cancer with limited spread
July 3, 2024
Summaries of recently published ECOG-ACRIN research results
July 3, 2024
Summaries and links to timely information about research results in medical journals, recognition of research leaders, and more
June 11, 2024
A Spring Group Meeting recap; a milestone for TMIST; a new myeloMATCH treatment trial
June 11, 2024
This phase 2 study is testing two variations of the triplet combination of azacitidine, venetoclax, and gilteritinib compared to standard therapy